Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
Stopped Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.
Conditions
Interventions
- DRUG: Prednisone
- DRUG: sunitinib
- DRUG: Placebo
- DRUG: Prednisone
Sponsor
Pfizer